Target
Recombinant human endostatin
1 abstract
Abstract
Real-world effectiveness and safety of PD-1 inhibitors combined with recombinant human endostatin and chemotherapy in refractory, recurrent/metastatic nasopharyngeal carcinoma.Org: Zhejiang Cancer Hospital, Chinese Academy of Sciences, Hangzhou Yirui Pharmaceutical Technology,